title: Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate.
abstract: BACKGROUND
  Although sentinel node (SN) biopsy has been applied for various types of solid tumors, its clinical significance is currently limited to the field of diagnostics. We developed a new translymphatic chemotherapy approach using a novel phospholipid polymer (PMB30W), which facilitates the dissolution of large amounts of paclitaxel. The purpose of the present study was to investigate the pharmacokinetics and antitumor effect of this conjugate (PTX-PMB30W) in a rat model.
  
  
  METHODS
  PTX-PMB30W was directly administered into the cecal submucosa or through the tail vein. The antitumor effect was compared between the two groups.
  
  
  RESULTS
  Paclitaxel concentrations in SNs remained constant over a 24-h period after local administration. Tumor growth was clearly suppressed by submucosal administration of PTX-PMB30W, resulting in a survival benefit compared to intravenous administration.
  
  
  CONCLUSIONS
  Translymphatic chemotherapy targeting SNs via direct administration of PTX-PMB30W appears feasible, and this strategy may be applicable to the multi-disciplinary management of early solid cancer.
authors.affiliation: Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. htakeuchi@a6.keio.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Oyama
authors.forename: Hiroya
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Sachiko
authors.initials: S
authors.lastname: Matsuda
authors.forename: Soji
authors.initials: S
authors.lastname: Ozawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Kitajima
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000737:chemistry; D001835:Body Weight; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D020128:Inhibitory Concentration 50; D008198:Lymph Nodes / Q000187:drug effects* / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008689:Methacrylates / Q000008:administration & dosage / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D051381:Rats; D021701:Sentinel Lymph Node Biopsy
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D008689:Methacrylates; D010767:Phosphorylcholine; C079200:poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate); D017239:Paclitaxel
keywords: 2-methacryloyloxyethyl phosphorylcholine; Translymphatic chemotherapy; micrometastasis; paclitaxel; sentinel node